10 Best Australian Stocks to Buy According to Billionaires

8. Mesoblast Limited (NASDAQ:MESO)

Number of Hedge Fund Holders: 2

Number of Billionaire Investors: 1 

Total Value of Billionaire Holdings: $3.56 million

Mesoblast Limited (NASDAQ:MESO) is an Australian company that creates and sells unique cell-based medicines to treat severe inflammatory conditions. It uses specialized technology to develop these “off-the-shelf” treatments. The company deals in cell-based medicines, inflammatory conditions, and off-the-shelf treatments.

On March 1, Jason McCarthy from Maxim Group maintained a Buy rating on the stock with a price target of $30. The analyst noted that the price of Ryoncil (the mesenchymal stromal cell therapy approved by the FDA) is approximately $1.55 million per treatment, which is justifiable due to its significant economic benefits. McCarthy believes that Ryoncil is a promising treatment for pediatric steroid-refractory acute graft vs host disease (SR-aGvHD), with a total addressable market of around $600 million. Moreover, the analyst also mentioned that Mesoblast Limited (NASDAQ:MESO) has secured $161 million through a private placement, which should support the commercialization of Ryoncil in the US. Considering the pipeline of the company, including a potential accelerated filing for Rexlemestrocel-L in Class IV heart failure, increases its valuation potential. Mesoblast Limited (NASDAQ:MESO) is one of the best Australian stocks to buy according to billionaires.